Search

Regeneron Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

662.01 0.89

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

649.44

Max

663.15

Schlüsselkennzahlen

By Trading Economics

Einkommen

-117M

727M

Verkäufe

-279M

3.6B

KGV

Branchendurchschnitt

16.236

60.149

EPS

9.47

Dividendenrendite

0.54

Gewinnspanne

20.17

Angestellte

15,343

EBITDA

-234M

967M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+24.19% upside

Dividenden

By Acuity

Dividendenrendite

Branchendurchschnitt

0.54%

2.24%

Nächstes Ergebnis

30. Juli 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-8.4B

70B

Vorheriger Eröffnungskurs

661.12

Vorheriger Schlusskurs

662.01

Nachrichtenstimmung

By Acuity

64%

36%

305 / 342 Ranking in Healthcare

Regeneron Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Juli 2026, 19:26 UTC

Regeneron Pharmaceuticals shares are lower today amid broader market declines driven by rising oil prices and geopolitical tensions. No specific company news was identified.

11. Juli 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reflecting a notable gain near the upper end of its one-month trading range.

10. Juli 2026, 19:26 UTC

Correlated Moves

Regeneron Pharmaceuticals Inc shares declined amid broader biotechnology sector pressures and geopolitical tensions, despite earlier reaching a session high before pulling back.

9. Juli 2026, 23:51 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours following a weak trading session, despite a report showing a decrease in initial jobless claims.

8. Juli 2026, 19:53 UTC

News

Regeneron Pharmaceuticals shares are lower, pressured by declines in the Biotechnology sector and a reduced price target of $730 from Morgan Stanley.

7. Juli 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, supported by stable performance and positioning above the 20-day moving average.

6. Juli 2026, 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline amid mixed market sentiment.

2. Juli 2026, 23:26 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, despite a lower-than-expected jobs report easing rate hike fears and boosting sentiment for some risk assets.

1. Juli 2026, 19:16 UTC

Regeneron Pharmaceuticals is trading higher, reflecting positive biotechnology sector performance. The stock remains above its 20-day moving average and near a one-month peak.

30. Juni 2026, 23:16 UTC

Regeneron Pharmaceuticals shares remain roughly flat in after-market trading, following three consecutive sessions of declines and no specific news identified.

29. Juni 2026, 23:06 UTC

News

Regeneron Pharmaceuticals will join the FDA's PreCheck Pilot Program to enhance domestic drug manufacturing. Shares are trading lower in after-market hours.

26. Juni 2026, 23:36 UTC

Regeneron Pharmaceuticals Inc shares are trading higher in after-market hours, moving within a notable range above their 20-day moving average.

25. Juni 2026, 23:16 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, retracing from an early peak following five consecutive daily gains. No specific news was identified.

24. Juni 2026, 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower after-market hours, continuing a decline since Wednesday's close amid positive sentiment in the financial sector.

23. Juni 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc shares are trading lower in after-market hours. Broader market trends may be influencing the stock's movement amid European market declines.

22. Juni 2026, 19:56 UTC

Social Media
News

Regeneron Pharmaceuticals' cemdisiran submissions accepted by the FDA and European Medicines Agency. Shares are gaining amid positive regulatory developments.

18. Juni 2026, 23:51 UTC

Regeneron Pharmaceuticals traded roughly flat in after-market hours, reflecting a slight decline since Thursday's close and remaining near the lower end of its one-month range.

17. Juni 2026, 19:53 UTC

Macro Event

Regeneron Pharmaceuticals is declining in Wednesday's session, despite positive U.S. retail sales data. Shares remain below their 20-day moving average.

16. Juni 2026, 19:16 UTC

Regeneron Pharmaceuticals Inc shares are lower today, with no specific news identified. Broader market sentiment may be affected by recent economic data.

15. Juni 2026, 13:36 UTC

Regeneron Pharmaceuticals Inc shares are lower in pre-market hours. The stock is near the lower end of its one-month range, indicating routine price action.

13. Juni 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market trading, though no specific news was identified to explain the movement.

12. Juni 2026, 19:16 UTC

Shares of Regeneron Pharmaceuticals are modestly higher today, gaining traction after a flat start. The stock remains below its 20-day moving average.

11. Juni 2026, 23:02 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, rebounding from earlier fluctuations despite no specific news to explain the movement.

10. Juni 2026, 23:11 UTC

Regeneron Pharmaceuticals is trading higher in after-market hours, supported by a rise in the Biotechnology sub-sector. The stock remains near its one-month low.

9. Juni 2026, 19:56 UTC

News

Regeneron Pharmaceuticals shares are higher following WHO's endorsement of its antibody therapy maftivimab for clinical trials against Bundibugyo ebolavirus.

8. Juni 2026, 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, recovering from earlier lows amid broader market dynamics influenced by recent U.S. jobs data.

5. Juni 2026, 20:07 UTC

Event

Regeneron Pharmaceuticals shares are higher as Teva launches AHZANTIVE, a biosimilar to Eylea, enhancing its ophthalmology portfolio and impacting Regeneron's competitive position.

4. Juni 2026, 19:56 UTC

Social Media
Event
News
Correlated Moves

Regeneron Pharmaceuticals is gaining momentum ahead of presentations at major medical conferences in June, showcasing new clinical data on key therapies.

3. Juni 2026, 23:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, following a session peak. No specific news was identified to explain the movement.

2. Juni 2026, 23:21 UTC

Regeneron Pharmaceuticals is trading higher in after-market hours, driven by gains in the Biotechnology sub-sector, marking a notable change from recent performance.

Peer-Vergleich

Kursveränderung

Regeneron Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

24.19% Vorteil

12-Monats-Prognose

Durchschnitt 814.81 USD  24.19%

Hoch 995 USD

Tief 641 USD

Basierend auf 21 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Regeneron Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

21 ratings

15

Buy

6

Halten

0

Sell

Stimmung

By Acuity

305 / 342 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat